These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8923571)

  • 1. MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients. A preliminary report.
    Slaap BR; van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1996 Oct; 127(4):353-8. PubMed ID: 8923571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report).
    Slaap BR; van Vliet IM; Westenberg HG; den Boer JA
    J Affect Disord; 1995 Jan; 33(1):31-8. PubMed ID: 7714306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.
    van Vliet IM; den Boer JA; Westenberg HG; Slaap BR
    J Clin Psychopharmacol; 1996 Aug; 16(4):299-306. PubMed ID: 8835705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response.
    Slaap BR; van Vliet IM; Westenberg HG; Den Boer JA
    J Affect Disord; 1996 Jun; 39(1):13-9. PubMed ID: 8835649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.
    Den Boer JA; Westenberg HG
    Psychopharmacology (Berl); 1990; 102(1):85-94. PubMed ID: 1697419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.
    Goddard AW; Woods SW; Sholomskas DE; Goodman WK; Charney DS; Heninger GR
    Psychiatry Res; 1993 Aug; 48(2):119-33. PubMed ID: 8416022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
    van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.
    Asnis GM; Hameedi FA; Goddard AW; Potkin SG; Black D; Jameel M; Desagani K; Woods SW
    Psychiatry Res; 2001 Aug; 103(1):1-14. PubMed ID: 11472786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.
    Nair NP; Bakish D; Saxena B; Amin M; Schwartz G; West TE
    Anxiety; 1996; 2(4):192-8. PubMed ID: 9160622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
    Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
    Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
    Sheline Y; Bardgett ME; Csernansky JG
    J Clin Psychopharmacol; 1997 Feb; 17(1):11-4. PubMed ID: 9004051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication treatments for panic disorder and social phobia.
    Stein MB
    Depress Anxiety; 1998; 7(3):134-8. PubMed ID: 9656095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.
    Sandmann J; Lörch B; Bandelow B; Härtter S; Winter P; Hiemke C; Benkert O
    Pharmacopsychiatry; 1998 Jul; 31(4):117-21. PubMed ID: 9754844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of newer antidepressants for panic disorder.
    Gorman JM
    J Clin Psychiatry; 1997; 58 Suppl 14():54-8; discussion 59. PubMed ID: 9418747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.
    van Vliet IM; den Boer JA; Westenberg HG
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):21-9. PubMed ID: 1638170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current concepts in the treatment of panic disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 18():16-21. PubMed ID: 10487251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of current treatment in panic disorder.
    den Boer JA; Slaap BR
    Int Clin Psychopharmacol; 1998 Apr; 13 Suppl 4():S25-30. PubMed ID: 9690962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks.
    Charney DS; Woods SW; Goodman WK; Heninger GR
    Am J Psychiatry; 1987 Aug; 144(8):1030-6. PubMed ID: 3037926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
    Mochcovitch MD; Nardi AE
    Expert Rev Neurother; 2010 Aug; 10(8):1285-93. PubMed ID: 20662754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.